Biogen Inc. disclosed that the U.S. FDA provided their endorsement for TOFIDENCE (tocilizumab-bavi) in an intravenous format, a biosimilar monoclonal antibody that references ACTEMRA.

AbbVie shared Phase 3 CANOVA trial results for the VenDex combo in treating relapsed or resistant multiple myeloma in patients with two or more prior treatments.

JCR Pharmaceuticals Co., Ltd. has disclosed critical findings from the midway 52-week data of its global research phase I/II involving JR-171 (lepunafusp alfa) in patients diagnosed with mucopolysaccharidosis type I.

Geron Corporation declared that the Marketing Authorization Application concerning imetelstat-a novel experimental telomerase inhibitor-has been accepted and validated by the EMA.

FDA accepts Priority Review of Odronextamab BLA for Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma.

IMUNON released preliminary PFS and OS statistics related to IMNN-001 from its Phase 1/2 OVATION 2 Investigation.

Structure Therapeutics has revealed encouraging results from its Phase 1b incremental dose study of its exclusive oral GLP-1 receptor agonist, GSBR-1290, in overweight or obese individuals.

Amicus Therapeutics has confirmed that the U.S. FDA has given the green light to Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) 65mg capsules.

These studies focused on the outcomes of the Phase 1b/2 study carried out on patients who had relapsed/refractory multiple myeloma and were undergoing treatment with Equecabtagene Autoleucel.

Mabwell announced the initiation of a Phase Ib/II trial with the first patient dosage. The study uses their novel Nectin-4 ADC (9MW2821) in conjunction with a PD-1 inhibitor for advanced or metastatic urothelial carcinoma.

ImmunoGenesis announced the first patient treatment in their Phase 1a/1b trial using IMGS-001 at The University of Texas MD Anderson Cancer Center.

Merck has declared that a fresh BLA for sotatercept has been approved for accelerated assessment by the U.S. FDA.